- Email: [email protected]
The rules of LYR anticancer therapy
1st ALC W Abstracts/Lung
Cancer 10 (1994) 386-394
survival. We suggest that the radiation fields should encompass the ipsilateral hilar and appropriate mediastinum, in stage IlIa patients. the bilateral supraclavicular regions should be included and an elective irradiation to whole brain with a dose of 30Gv in 2 weeks should also be considered for patients with adenocarcinoma. Ninety-seven patients with squamous cell lung cancer were randomized to receive postoperative radiotherapy (S+Rgroup, 46 patients) or no treament (S group, 5 1 patients). The results were obtained as follows: I. The post-operative radiotherapy did not improve survival (3.5 year survival rate was 4 I .7% (15/36), 53.8% (7113) vs 58.8% (20/34), 52.6% (lO/l9)). 2. The post-operative radiotherapyreducedthelocal relapse( 13%6/46vs29.4%(15/51), P = 0.05). 3. Distant metsstatis was also the chief cause of fhilure in the patients with squamous cell lung cancer (30.4% (14146) vs 29.4% (1515 I)).
Management ofsuperior venacava syndrome (SVCS)with lung cancer - analysis of 320 patients Yin W-B, Zhang H-X, Dept. of Radiation Oncology, Cancer Hospital, Chinese Academy ofMedical Sciences. Betjing, China. From May 1959 to December 1990,320 patients with carcinoma of the lung presenting with SVCS were treated in our hospital. ReliefofSVCS wasobservedin 89.4%(286 of320)ofpatientsand complete relief of SVCS was obtained in 64.1% (205 of 320) of patients. Complete relief rate of SVCS was 7 I .6% in the primary ndiotheraprgroup~d26.4%inthechemothenpygroup(P
389
The aim of opention is to raise patient’s survival rate with a good quality of life, however. excessive resection in patients whose cardiopulmonary condition is poor or late cases would be to reduce their postoprative survival rate and quality of life. The characteristics of LYR anticancer drugs. Yurun L, Zhenghui L. Most of LYR clinic’s I.500 patients were politely declined by large hospitals and informed regretfully that their condition was terminal and not treatable. After LYR therapy, health was restored to varying extent. and some are in perfect health and still alive after 3 years. According to a long period of clinical practice, there are ten distinguishing features of the LYR anticancer drugs developed by us. Theseareas follows: (1) Ithas reliablecurativeeffects; (2) it has rapid effect (even within 24 h); (3) it e.xhibits no toxic or side effect: (4) it is convenient for oral use; (5) it shows gocd response in dying patients with 311 kinds of carcinomas (primary or metastatic carcinoma) and for those who were inoperable; (6) it reduced cancerous high fever, from its peak to the normal without injection; (7) it relieves patients From carcinomatous pain without the use of dolantin. opium or morphine; (8) it controls pleural effusion and prolongs the intervals between abstractions; (9) it corrects h>poproteinemia: (IO) it restores agood appetite. In a word, LYR anticancer drugs are safe for use on any hind of cancer and have been made available to doctors for the purpose of lengthening the life span of patients with carcinomatosis, including SCC. The rules of LYR anticancer therapy Yurun L, Zhenghui L. No one medicine has all the desired characteristics, so for each patient, and even in different stages ofdisease, a certain number and amount of various anticancer drugs must be used. Moderation and a reasonable dose shouldbe the main consideration in taking LYR therapy. Taking a combination of traditional Chinese and Western medicines, qtiems with lung cance require neither operation nor admission to hosptial. The rules of LYR anticancer therapy areas follows: (I) use a small dosage; (2) use a series of compound oral anticancer drugs; (3) take various drugs simultaneously: (4) use over a long period of time: (5) treat continuously. If we act on the above rules, we can obtain a curative effect total effective rate of 9 I%. significant effective rate of 16% and average of effective rate of 75%. During the treatment course, the patients were treated by methods quite different from those used to treat lung cancer in China today. My patients were often cured so rapidly and dramatically that they called LYR anticancer drugs “wonder” or “miracle” drugs: LYR therapy depends on Western medicines to inhibit the growth of cancer cells and on traditional Chinese medicines to raise their immunocompetence. In short, the treatment of lung cancer is most effective when we use combined traditional Chinese medicine and Western medicines.
Cancer 10 (1994) 386-394
survival. We suggest that the radiation fields should encompass the ipsilateral hilar and appropriate mediastinum, in stage IlIa patients. the bilateral supraclavicular regions should be included and an elective irradiation to whole brain with a dose of 30Gv in 2 weeks should also be considered for patients with adenocarcinoma. Ninety-seven patients with squamous cell lung cancer were randomized to receive postoperative radiotherapy (S+Rgroup, 46 patients) or no treament (S group, 5 1 patients). The results were obtained as follows: I. The post-operative radiotherapy did not improve survival (3.5 year survival rate was 4 I .7% (15/36), 53.8% (7113) vs 58.8% (20/34), 52.6% (lO/l9)). 2. The post-operative radiotherapyreducedthelocal relapse( 13%6/46vs29.4%(15/51), P = 0.05). 3. Distant metsstatis was also the chief cause of fhilure in the patients with squamous cell lung cancer (30.4% (14146) vs 29.4% (1515 I)).
Management ofsuperior venacava syndrome (SVCS)with lung cancer - analysis of 320 patients Yin W-B, Zhang H-X, Dept. of Radiation Oncology, Cancer Hospital, Chinese Academy ofMedical Sciences. Betjing, China. From May 1959 to December 1990,320 patients with carcinoma of the lung presenting with SVCS were treated in our hospital. ReliefofSVCS wasobservedin 89.4%(286 of320)ofpatientsand complete relief of SVCS was obtained in 64.1% (205 of 320) of patients. Complete relief rate of SVCS was 7 I .6% in the primary ndiotheraprgroup~d26.4%inthechemothenpygroup(P
389
The aim of opention is to raise patient’s survival rate with a good quality of life, however. excessive resection in patients whose cardiopulmonary condition is poor or late cases would be to reduce their postoprative survival rate and quality of life. The characteristics of LYR anticancer drugs. Yurun L, Zhenghui L. Most of LYR clinic’s I.500 patients were politely declined by large hospitals and informed regretfully that their condition was terminal and not treatable. After LYR therapy, health was restored to varying extent. and some are in perfect health and still alive after 3 years. According to a long period of clinical practice, there are ten distinguishing features of the LYR anticancer drugs developed by us. Theseareas follows: (1) Ithas reliablecurativeeffects; (2) it has rapid effect (even within 24 h); (3) it e.xhibits no toxic or side effect: (4) it is convenient for oral use; (5) it shows gocd response in dying patients with 311 kinds of carcinomas (primary or metastatic carcinoma) and for those who were inoperable; (6) it reduced cancerous high fever, from its peak to the normal without injection; (7) it relieves patients From carcinomatous pain without the use of dolantin. opium or morphine; (8) it controls pleural effusion and prolongs the intervals between abstractions; (9) it corrects h>poproteinemia: (IO) it restores agood appetite. In a word, LYR anticancer drugs are safe for use on any hind of cancer and have been made available to doctors for the purpose of lengthening the life span of patients with carcinomatosis, including SCC. The rules of LYR anticancer therapy Yurun L, Zhenghui L. No one medicine has all the desired characteristics, so for each patient, and even in different stages ofdisease, a certain number and amount of various anticancer drugs must be used. Moderation and a reasonable dose shouldbe the main consideration in taking LYR therapy. Taking a combination of traditional Chinese and Western medicines, qtiems with lung cance require neither operation nor admission to hosptial. The rules of LYR anticancer therapy areas follows: (I) use a small dosage; (2) use a series of compound oral anticancer drugs; (3) take various drugs simultaneously: (4) use over a long period of time: (5) treat continuously. If we act on the above rules, we can obtain a curative effect total effective rate of 9 I%. significant effective rate of 16% and average of effective rate of 75%. During the treatment course, the patients were treated by methods quite different from those used to treat lung cancer in China today. My patients were often cured so rapidly and dramatically that they called LYR anticancer drugs “wonder” or “miracle” drugs: LYR therapy depends on Western medicines to inhibit the growth of cancer cells and on traditional Chinese medicines to raise their immunocompetence. In short, the treatment of lung cancer is most effective when we use combined traditional Chinese medicine and Western medicines.